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The relatively high variability of the hepatitis C virus (HCV) envelope proteins E1 and E2 suggests that parts of these
proteins other than the hypervariable region 1 (HVR1) might be involved in the induction of virus neutralizing antibodies. To
test this hypothesis, two HCV proteins, pE1 and pE2D, were generated by in vitro translation. They represent amino acids
174–337 of E1 and 411–688 of E2, respectively, of isolate HCV-AD78; the protein pE2D contained no HVR1. As a control,
protein pG.HVR1, which represents amino acids 384–410 of HVR1 of isolate HCV-AD78, was expressed separately. These
three proteins were used in an immunoprecipitation assay to detect the presence of antiviral antibodies in sera of patients
infected with the same isolate of HCV (HCV-AD78). Sera were obtained 4–8 months postinfection from patients who later
resolved an acute infection or developed chronic liver disease. A high prevalence of antibodies (up to 85.7%) against pE1 and
pE2D could be detected in both groups of patients, suggesting that these forms of the HCV envelope proteins contain B-cell
epitopes. The antibody responses against proteins pE1 and pE2D did not differ significantly between patients with resolving
or chronic infection, whereas antibodies against protein pG.HVR1 were associated with resolution of infection. Rabbit
antisera raised against pE1 and pE2D were tested for their ability to neutralize the binding of HCV to susceptible cells in
tissue cultures. The results suggested that although a few B-cell epitopes outside of HVR1 can induce virus neutralizing
antibodies, these antibodies are probably not associated with the resolution of infection. © 1998 Academic Press
INTRODUCTION
Hepatitis C virus (HCV) is the major causative agent of
parenterally transmitted hepatitis (Choo et al., 1989). It is
associated with the majority of cases of posttransfusion
hepatitis and community-acquired hepatitis worldwide
(Alter et al., 1992,1989). Chronic HCV infection is often
followed by severe liver diseases, including liver cirrho-
sis and hepatocellular carcinoma (Alter, 1994; Saito et al.,
1990; Miyamura et al., 1990). The high rate of chronic
outcome of HCV infection is possibly due to an immune
escape of the virus (Weiner et al., 1995,1991). Clearance
of virus most probably involves isolate-specific immune
response because the genome of HCV possesses sig-
nificant genetic heterogeneity (Bukh et al., 1995) and
exists as a quasispecies population (Martell et al., 1992).
Immunization of chimpanzees with heterodimers of
the two HCV envelope proteins E1 and E2 led to protec-
tion from challenge with a homologous isolate of HCV
(Choo et al., 1994). Such protection seemed to correlate
with the titer of neutralizing antibodies (Rosa et al., 1996).
On the other hand, reinfection of chimpanzees and pa-
tients with other isolates have been observed, suggest-
ing isolate-specific neutralization (Farci et al., 1992). Neu-
tralizing antibodies were detected in sera of patients
with chronic hepatitis C (Shimizu et al., 1994; Zibert et al.,
1995; Rosa et al., 1996). Envelope-specific antibodies
directed against a small region, located at the N-termi-
nus of E2 and termed hypervariable region 1 (HVR1),
have been postulated to be capable of neutralizing HCV
(Zibert et al., 1995; Weiner et al., 1991). However, antibod-
ies directed to epitopes of envelope proteins, other than
HVR1, may also be important for neutralization (Rosa et
al., 1996; Zibert et al., 1995).
Antibodies specific to envelope proteins E1 or E2 have
been detected with prevalences ranging from 9 to 97%
(Lanford et al., 1993; Yan et al., 1994; Hada et al., 1992;
Harada et al., 1995; Lesniewski et al., 1995). These anti-
bodies seem to persist in chronically infected patients
(Chien et al., 1993). However, these studies used the
same antigen for antibody detection in sera of patients
infected by different isolates and may have missed iso-
late-specific immune responses. In addition, the time
points of infection were mostly unknown in the patients
studied. The prevalence of envelope-specific antibodies
during the early phase of infection may differ in patients
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who have acute self-limiting or develop chronic infec-
tions. Such investigations with isolate specific proteins
have been recently performed for HVR1 (Allander et al.,
1997; Zibert et al., 1997b).
We investigated the early antibody response (months
4–8 p.i.) in a group of patients infected by the same
isolate of HCV (HCV-AD78). This single source outbreak
was caused by a contaminated immunoglobulin (Ditt-
mann et al., 1991). Patients had either self-limiting infec-
tions or developed chronic hepatitis C infections. Two
different sets of experiments were performed in order to
characterize the antibody response against regions of
the HCV envelope which are located outside of HVR1. We
first investigated the prevalence of antibodies directed
against three proteins of HCV-AD78; pE1, pE2D (E2 lack-
ing HVR1), and also pG.HVR1 by an immunoprecipitation
assay. Second, the significance of antibodies directed
against epitopes outside of HVR1 was characterized
using rabbit sera which were raised against regions of
E1 and E2. These sera were tested for their ability to
neutralize binding of HCV-AD78 to human fibroblasts (in
vitro neutralization of binding).
RESULTS
Antibodies directed against E1, HVR1, or E2D in
patients with acute self-limiting and chronic infections
caused by HCV-AD78
The distribution of a quasispecies of HCV-AD78 which
is present in the contaminated immunoglobulin (IgG)
was demonstrated by cDNA cloning and sequencing of
HVR1 using different aliquots of the inoculum and RT–
PCR primers (Zibert et al., 1995; Hohne et al., 1994).
These analyses revealed only limited sequence hetero-
geneity, suggesting a HCV contamination of the IgG
preparation by one donor only. In order to characterize
the envelope-specific antibody response in patients who
had self-limiting or developed chronic infections after
administration of the contaminated IgG, an immunopre-
cipitation assay with three in vitro translated envelope-
specific proteins, termed pE1, pG.HVR1, and pE2D, was
performed (Fig. 1A). The proteins corresponded to the
main variant of isolate HCV-AD78. The patient sera an-
alyzed were obtained at early time points after infection
with HCV-AD78. Protein pE1 encodes aa 174–337 and
lacks the putative transmembrane region. Protein
pG.HVR1 encodes the amino acids of HVR1 (aa 384–410)
which also include the two amino terminal insertions
present in isolate HCV-AD78 (Zibert et al., 1997a; Hohne
et al., 1994). For immunoprecipitation analysis, this 29-
amino-acid region was fused to GST. Protein pE2D en-
codes the remainder of E2 (aa 411–688) and lacks HVR1
and the putative transmembrane region (Fig. 1A). The
three proteins were mixed after in vitro translation at
equal amounts of radioactivity. GST protein was included
as a negative control. After SDS–PAGE (Fig. 2A) the
protein bands showed the expected molecular weights
of 20 kDa for pE1 (lane 1), 27 kDa for GST (lane 2), 30 kDa
for pG.HVR1 (lane 3), and 31 kDa for pE2D (lane 4).
Three examples of immunoprecipitations are given in
Fig. 2B. Sera of patient 1 (lane 1) and patient 2 (lane 2)
immunoprecipitated all three proteins, while the serum of
patient 3 (lane 3) precipitated only pE1 and pG.HVR1.
Different relative intensities of the individual protein
bands were observed (data not shown), indicating that
titers of antibodies directed to these proteins differed for
each serum. Protein pG.HVR1 was more efficiently pre-
cipitated than pE1 and pE2D with most of the patient
sera (examplified in Fig. 2B).
Sera of 37 patients which were obtained between
FIG. 1. Location of envelope-specific proteins of HCV. (A) Proteins used for immunoprecipitation. pE1, pG.HVR1, and pE2D were derived by in vitro
translation. The putative transmembrane regions (hatched bars) are lacking. Hypervariable region 1 (HVR1, black bar) of HCV-AD78 was fused to GST
(gray dot). (B) Proteins used for immunization of rabbits. pGST.E1, pGST.E2a, and pGST.E2b are GST fusion proteins expressed in E. coli. HVR1 is not
included in these proteins.
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months 4 and 8 p.i. were analyzed by immunoprecipita-
tion. Sera of 21 patients who had acute self-limiting
infections and 16 sera of patients who later developed
chronic infections were compared. Only 1 of 37 patients
did not contain antibodies to either of the three proteins
(Table 1). Protein GST alone was not precipitated. Anti-
bodies against HVR1 had the highest prevalence (95.2%)
in sera of patients with acute self-limiting infection of
HCV-AD78. The prevalence of antibodies directed
against pE1 and pE2D was also high. Eighteen of 21
(85.7%) patients with acute self-limiting infection had
antibodies against pE1 as well as against pE2D. In pa-
tients with chronic infections the prevalence of antibod-
ies directed against pE1 and pE2D was lower, but not
with statistical significance. In this group, 13 of 16 pa-
tients (81.2%) had antibodies against both proteins. Only
2 patients with acute self-limiting infection or chronic
infection were negative for antibodies against both pro-
teins, and 2 other patients of each group were negative
for antibodies to either of the two proteins. In contrast to
antibodies against pE1 and pE2D, the prevalence of
antibodies against pG.HVR1 differed significantly (P ,
0.005) between the two patient groups. Twenty of 21
(95%) patients with acute self-limiting infections had
such antibodies, while only 5 of 16 (31.2%) patients with
chronic infections were anti-HVR1 positive (Table 1).
Both patients who did not contain antibodies against pE1
and pE2D were positive for anti-HVR1. Fifteen anti-HCV-
negative sera did not precipitate any of the three pro-
teins.
Characterization of rabbit sera directed to epitopes
outside of HVR1
Antibodies directed to HVR1 were suggested to be
capable of in vitro neutralization of HCV (Farci et al.,
1996). The significance of antibodies directed against the
part of the HCV envelope that does not contain the HVR1
with respect to virus neutralization is not known. In order
to investigate whether such antibodies are important for
neutralization of HCV, we raised antisera to E1 and E2
(lacking HVR1) in rabbits and characterized these sera
by their ability to neutralize the binding of HCV to cells
(Zibert et al., 1995; Shimizu et al., 1994). E1- and E2-
specific proteins were expressed in E. coli (Fig. 3). Pro-
tein pGST.E1 (Fig. 1) encodes almost complete E1 in
fusion to GST (Fig. 3, lane 1). However, the complete E2
could not be expressed as was reported before (Mita et
al., 1992) and was represented by two protein fragments
termed pGST.E2a and pGST.E2b (Fig. 1; Fig. 3, lanes 2
and 3). These proteins were used for immunization of
rabbits after purification of major protein bands showing
the expected molecular weights of approximately 48 kDa
each.
FIG. 2. In vitro translation and immunoprecipitation of HCV envelope-
specific proteins. (A) Autoradiograph after SDS–PAGE of in vitro trans-
lated pE1 (lane 1), GST (lane 2, control), pG.HVR1 (lane 3), and pE2D
(lane 4). (B) Immunoprecipitation of in vitro translated proteins. All four
proteins were mixed at almost equal amounts of radioactivity and
immunoprecipitated by three patient sera (lanes 1–3). The film was
exposed for 7 days. Lane M, molecular weight markers (kDa).
TABLE 1
Immunoprecipitation of in Vitro Translated HCV Envelope Proteins pE1, pG.HVR1, and pE2D
Patients No. of sera examined Month p.i. (mean)
No. of positive sera (%)







Acute self-limiting infection 21 4–7 (5.4) 18 (85.7%) 20 (95.2%) 18 (85.7%)
Chronic infection 16 4–8 (5.9) 13 (81.2%) 5 (31.2%) 13 (81.2%)
Anti-HCV negative 15 — 0 0 0
FIG. 3. SDS–PAGE of partially purified HCV envelope proteins. Coo-
massie stain after SDS–PAGE. Partially purified E. coli lysates (approx-
imately 5 mg of protein/lane) were applied to the gel. The arrow
indicates major bands of the respective fusion proteins. For immuni-
zation of rabbits minor protein bands were removed after blotting onto
nitrocellulose filter. Lane 1, pGST.E1; lane 2, pGST.E2a; and lane 3
pGST.E2b. Lane M, molecular weight markers (kDa).
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Five rabbits were immunized and the specificity of the
resulting sera (R1–R5) was demonstrated by immunopre-
cipitation (Fig. 4) and by ELISA (Fig. 5). As expected, in
vitro translated pE1 was precipitated by rabbit serum R1,
and pE2D by sera R2–R5, respectively. Rabbit serum R3
seemed to precipitate these proteins rather inefficiently.
A threefold amount of serum had to be used to yield
similar amounts of radioactivity. The HCV E1-specific
(R1) and the four HCV E2-specific rabbit sera (R2–R5)
were characterized by ELISA using overlapping peptides
(20-mers, overlapping by 10 amino acids) covering aa
171–340 or aa 411–690 of HCV-AD78, respectively. Ex-
cept serum R3, all rabbit sera recognized one or more
peptides (Fig. 5). Serum R1 reacted to peptides repre-
senting aa 231–250 and 281–230. Serum R2 reacted to
five peptides, which represent aa 441–460, aa 511–530,
and aa 561–599. Sera R4 and R5, which were raised
against the same protein (pGST.E2b), recognized two
different sets of peptides (aa 481–510 and aa 641–680,
respectively).
To determine the importance of HCV envelope-specific
antibodies directed to epitopes outside of HVR1, sera
R1–R5 were tested for their ability to neutralize the bind-
ing of HCV-AD78 to human fibroblast cells (VH3) (Table
2). These cells have been shown to bind HCV and sup-
port replication of HCV (Zibert et al., 1995). The experi-
ments were carried out at least three times with the
same results and a HVR1-specific rabbit serum which
has previously been shown to neutralize binding of HCV-
AD78 (Zibert et al., 1997a) was used as a positive control
(data not shown). Serum R2 (raised against aa 411–613)
was able to block viral attachment. In contrast, rabbit
serum R3, which was raised against the same protein,
but only inefficiently precipitated E2 (Fig. 4) and showed
no antibodies against E2-specific peptides (Fig. 5), did
not neutralize viral binding. Rabbit sera R1, R4, and R5
could not neutralize binding of HCV-AD78 even at high
concentrations (1:5).
DISCUSSION
Humoral immune response to the HCV envelope is
considered essential for elimination of the virus. How-
ever, the analysis of antiviral antibodies during the nat-
ural course of infection is hampered by the high variabil-
ity of the envelope sequences found in different isolates.
Therefore, our study included patients infected with the
same isolate of HCV with known time points of infection
and characterized by a long-term follow-up of infection.
Analysis of such a well-characterized patient group
should allow us to determine some characteristics of
anti-E1 and anti-E2 response in acute self-limiting or
chronic infections. It is likely that the sera studied here,
obtained after 4–8 months p.i., contained antibodies
which are mainly directed to the amino acid sequence of
the virus present in the contaminated anti-D IgG (HCV-
AD78), although the amino acid sequence of the HCV
envelope was shown to rapidly accumulate mutations
within a few months of HCV infection (Kato et al., 1994;
Higashi et al., 1993; Kurosaki et al., 1994; Taniguchi et al.,
1993; van Doorn et al., 1995; Kojima et al., 1994). Isolate-
specific antibodies which may have been missed in
other studies of the HCV anti-envelope response
(Saracco et al., 1994; Lesniewski et al., 1995; Yuki et al.,
1996; Chien et al., 1993) are likely to be detected by
analysis of our patient group.
Different forms of the envelope proteins E1 and E2
have been used for antibody detection in sera of HCV-
FIG. 5. Peptide ELISA. Antibodies of rabbit sera R1, R2, R4, and R5
were analyzed by ELISA. The y axis shows OD405 values above 0.2. The
x axis indicates peptides 1–16 (R1) or 1–27 (R2, R4, and R5), which
cover aa 171–340 and aa 411–690 of HCV-AD78, respectively. Amino
acid positions of reactive peptides are depicted above bars. Serum R3
did not react with any peptide (not shown).
FIG. 4. Immunoprecipitation of in vitro translated pE1 and pE2D,
respectively. Lanes 3–7, immunoprecipitation by respective rabbit sera
R1–R5.
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infected patients. The rate of antibody detection was
generally lower when denatured proteins were used (Yan
et al., 1994; Ray et al., 1994) compared to putative native,
glycosylated proteins (Chien et al., 1993; Harada et al.,
1995; Ray et al., 1994; Lesniewski et al., 1995), suggesting
that a substantial portion of the patient antibodies are
directed to nonlinear B-cell epitopes of the HCV enve-
lope. Using proteins pE1 and pE2D, which are nonglyco-
sylated, partially truncated forms of the HCV envelope
generated by in vitro translation, specific antibodies
were detected with a rate of up to 85.7%, which is almost
as high as the rates observed with potentially native
envelope proteins (Chien et al., 1993; Yuki et al., 1996).
This suggests that proteins pE1 and pE2D contain major
B-cell epitopes which are recognized by antibodies of
the majority of HCV-infected patients during the early
phase of infection (months 4–8 p.i.). However, the rate of
antibody detection observed here could have been
slightly higher when native envelope proteins of HCV,
e.g., by using heterodimers of E1 and E2 expressed by
recombinant vaccinia viruses, had been used. This latter
form of the HCV envelope was suggested to be the
functional unit of the virion (Dubuisson et al., 1994) and
induced an immune response in chimpanzees which
could prevent infection with HCV (Choo et al., 1994).
Although our own studies involving HCV envelope pro-
teins expressed by recombinant vaccinia virus led to
similar high rates of antibody detection (data not shown)
compared to those of other studies (Chien et al., 1993;
Yuki et al., 1996), such proteins have little value for
investigations of the specific antibody response outside
of HVR1. The native proteins which also include HVR1
could distort the determination of the specific antibody
response to other regions of the envelope since HVR1
includes immunodominant B-cell epitopes (Scarselli et
al., 1995; Zibert et al., 1997a). On the other hand, deletion
of HVR1 which is located adjacent to hydrophobic se-
quences involved in the translocation of the proteins into
the ER would possibly abrogate the correct processing
of the HCV envelope and also modify the folding of E2.
The association of antibodies against HVR1 with re-
solving from HCV infection was reported previously (Al-
lander et al., 1997; Zibert et al., 1997b). However, the
antibody response against B-cell epitopes outside of
HVR1 was not addressed in these investigations (Zibert
et al., 1997b) or was not assessed with isolate-specific
proteins that exclude HVR1 (Allander et al., 1997). In the
current study, we demonstrated the marked antibody
response against the isolate specific envelope proteins
lacking HVR1 in patients who either resolved the infec-
tion or developed chronic liver disease (Table 1). It
should be noted, however, that although we did not
detect differences of the antibody response between
these patient groups using proteins pE1 and pE2D, our
immunoprecipitation assay might not measure antibod-
ies appropriately (e.g., neutralizing antibodies) directed
to single epitopes. In addition, subtle differences of an-
tibody titers against pE1 and pE2D could not be deter-
mined, although our previous investigation of HVR1 sug-
gests that such differences might not be significant for
the course of HCV infection (Zibert et al., 1997b). Never-
theless, our study using an isolate-specific test system
shows that antibodies to epitopes of the envelope pro-
teins lacking HVR1 appear during the early phase of HCV
infection but can be associated with neither the resolu-
tion nor the development of a chronic infection.
The existence of HCV isolate-specific neutralizing an-
tibodies was shown by experimental infection of chim-
panzees (Farci et al., 1996,1994) and suggested by tissue
culture experiments (Zibert et al., 1997a; Rosa et al., 1996;
Shimizu et al., 1994). For other viruses, e.g., HIV, it is
known that some of the neutralizing antibodies are di-
TABLE 2









R1 pGST.E1 (aa 174–337) 1 aa 231–250; 281–320 —
Pre R1a — 2 — NDb
R2 pGST.E2a (aa 411–613) 1 aa 441–460; 511–530; 561–600c 1
Pre R2 — 2 — —
R3 pGST.E2a (aa 411–613) (1)d — —
Pre R3 — 2 — ND
R4 pGST.E2b (aa 481–688) 1 aa 481–510 —
Pre R4 — 2 — ND
R5 pGST.E2b (aa 481–688) 1 aa 641–680 —
Pre R5 — 2 — ND
a Rabbit serum taken prior immunization (pre serum).
b Not determined.
c Amino acids of reactive peptides.
d R3 had to be used at high concentration (1:15), compared to all other sera (1:100).
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rected against epitopes located outside the extremely
variable regions (Sattentau and Moore, 1995). For HCV
such evidence was also obtained by several authors
(Zibert et al., 1995; Rosa et al., 1996; Choo et al., 1994).
We characterized antibodies of five rabbit sera directed
to epitopes other than HVR1 by their ability to neutralize
binding of HCV to cells (Table 2). One rabbit serum (R2;
immunized with aa 411–613) contained such antibodies.
HCV-specific antibody titers in the rabbit sera were
rather low. The absence of antibodies which block viral
binding in sera R1 and R3–R5 might be due to inefficient
presentation of important epitopes in the SDS-denatured
antigens (Fig. 3). On the other hand, our results suggest
that at least one epitope which might be important for
induction of neutralizing antibodies resides outside of
HVR1. Whether this epitope is located in one of the three
regions identified by ELISA using serum R2 (Fig. 5) has to
be established by monospecific antisera. Serum R3 ob-
tained after immunization with the same protein as R2
did not neutralize binding of HCV-AD78, probably due to
the absence of antibodies directed to these epitopes or
due to the lower titer of HCV-specific antibodies (Fig. 4).
Further studies are needed to investigate whether the
presence of antibodies directed to these epitopes can be
correlated with resolving from disease.
MATERIALS AND METHODS
Patient sera
Sera of 37 patients, who received a HCV-contaminated
anti-D immunoglobulin in 1978/1979 (isolate HCV-AD78)
(Dittmann et al., 1991), were studied. Sera were obtained
shortly after administration of the immunoglobulin
(months 4–8 p.i.). Twenty-one sera were derived from
patients who, as diagnosed retrospectively, resolved
HCV infection and 16 sera were obtained from patients
who developed chronic infections. Acute self-limiting in-
fections were characterized by initial (months 2–7 p.i.)
elevated ALT levels that dropped thereafter and re-
mained normal in the follow-up period of up to 17 years
p.i. Sera were HCV RT–PCR negative in follow-up. In
contrast, chronically infected patients were consecu-
tively RT–PCR positive and had elevated ALT levels
throughout follow-up. Fifteen sera which were anti-HCV,
anti-HBs, and anti-HIV negative served as negative con-
trols.
Cloning of E1 and E2 of HCV-AD78
RNA preparation of HCV-AD78 and RT were performed
as described previously (Zibert et al., 1995). Nested PCR
was carried out using 5 ml of respective cDNA mixture,
0.3 U Taq DNA polymerase (Promega, U.S.A.), and 50
pmol of primers in a total volume of 50 ml. For reverse
transcription of E1, RT-antisense (A) primer 59-GT-
CAACGCCAGCAAAGAGTAGCAT-39 (nt position 1475,
Kato et al., 1990) was used. The first round of PCR was
with RT primer and the sense primer (S) 59-TTCTGGAG-
GACGGCGTGAACTA-39 (788). The second round of PCR
was performed with primers S 59-TGCTCTTTCTCTATCT-
TCCTC-39 (843) and A 59-GTAGCATCACAATCAAGAC-
CTT-39 (1458). For cloning, this cDNA was amplified with
tagged primers S 95-GCTTCCATGGCTTTCTCTATCTT-39
(NcoI) and A 59-TTGTGGGACTCGAGGTAGCTGCATA-39
(XhoI). After digestion with the corresponding enzymes,
the cDNA was cloned into the NcoI and XhoI sites of
vector pTM1 (Moss et al., 1990). The resulting plasmid,
termed pTME1.5, encodes amino acids 174–337. Cloning
of a 1.3-kb fragment encoding E2 was described previ-
ously (Zibert et al., 1995). This cDNA was cloned into
vector pTM1 after reamplification of E2 with tagged prim-
ers S 59-CAGAGCCATGGGCGTCTTGATTGTGATGCTAC-
TC-39 (NcoI) and A 59-GGTGCAAGCTTCAGATGTACCA-
GGCGGCGCAG-39. The resulting cDNA was digested
with NcoI and ligated (sticky/blunt) into the NcoI/SmaI
sites of vector pTM1. The resulting plasmid was termed
pTM18.19 and encodes aa 371–778.
In vitro translation and immunoprecipitation
Plasmids pTME1.5, pTM18.19, and G.HVR1.A (see be-
low) served as templates for PCR of envelope-specific
regions. Individual sense primers were preceeded by a
T7 promotor sequence followed by an ATG start codon
and the HCV envelope-specific sequence. In case of
GHVR1.A, the primer contained the GST (glutathione S-
transferase)-specific sequence. Five micrograms of the
PCR products served as a template for in vitro transcrip-
tion using T7 RNA polymerase (20 U) (Promega) in a
volume of 30 ml. Transcription was carried out for 60 min
at 37°C. One microliter of the resulting transcripts was
translated in 30 ml of rabbit reticulocyte lysate (Promega)
in the presence of [35S]methionine (30 mCi) for 60 min at
30°C. Proteins were analyzed on 17% sodium dodecyl
sulfate (SDS)–polyacrylamide gels. Gels were dried and
exposed to Kodak-XOMAT film. For immunoprecipitation,
reticulocyte lysates (2–4 ml, depending on the amount of
radioactivity of the respective proteins) were diluted with
300 ml buffer 1 (2% Triton X-100, 50 mM Tris–HCl, pH 8.0,
5 mM EDTA). Either 1 ml of patient serum or 5–15 ml of
rabbit sera was used for immunoprecipitation. Incuba-
tion time was 2 h at 4°C. Protein A–Sepharose 4B (Phar-
macia, Sweden) (20 mg bed volume) was then added to
the immune complexes and incubated for 30 min under
vigorous shaking. The complexes bound to protein
A–Sepharose were washed three times with buffer 1 and
once with buffer 1 lacking Triton X-100. Retained immu-
nocomplexes were analyzed by SDS–PAGE followed by
autoradiography. Films were exposed for 7 days and the
presence of individual bands was determined by visual
inspection. Longer exposition times (3 weeks) did not
yield different patterns of immunoprecipitated protein
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bands. Negative controls (no serum added, anti-HCV-
negative patient sera) were also included.
Subcloning of E1 and E2 for expression in e. coli
Plasmid pTME1.5 served as template for PCR amplifi-
cation of E1 with primers S 59-GAAAAACACGATAATAC-
CATGGCTTTCTCT-39 (NcoI) and A 59-TTGTGGGACTC-
GAGGTAGCTGCATA-39 (XhoI). This cDNA was cloned
into Escherichia coli expression vector pGEX-KG (Guan
and Dixon, 1991). The resulting plasmid was termed
GST.E1. Plasmid pTM18.19 was used as a template for
PCR of three E2-specific fragments, which were cloned
into pGEX-KG. The following primers were used for
PCR. G.HVR1.A: S 59-CGACCATGGGTGGACCCACCCGC-
ACG-39 (1481, NcoI) and A 59-CCAGCTGCCGTTGAA-
GCTTCAGATTTTC-39 (1555, HindIII); GST.E2a: S 59-CGG-
CCATGGTCGAGCTTATAAACACCAAC-39 (NcoI) and A 59-
GGTGGATCCAAAGCCTGTATGGGTA 39 (BamHI); GST.E2b:
S 59-CGGCCATGGACCAGAGGCCCTACTGC-39 (NcoI) and
A 59-GGCGGATCCACCAGTGGACAGAGCCGG-39 (BamHI).
The PCR products were digested with the corresponding
enzymes and inserted into the multiple cloning site of
pGEX-KG. The resulting plasmids were termed G.HVR1.A,
encoding the main variant of HVR1 (aa 384–410) (Zibert et
al., 1995), GST.E2a (aa 411–613), and GST.E2b (aa 486–
688), respectively (Fig. 1B).
Expression and purification of recombinant E1 and E2
E. coli strain XL1-blue carrying the respective plasmids
was grown overnight in LB medium containing ampicillin
(100 mg/ml). After dilution (1:50) with 23 YT medium (100
mg/ml ampicillin) cells were grown at 37°C to an OD600 of
1.3. Induction of expression was started by addition of IPTG
(1 mM). After 4 h of incubation, cells were harvested by
centrifugation. Lysis was performed according to Marston
(1987) with a lysis buffer (1 mM EDTA, 100 mM NaCl, 50 mM
Tris, pH 8) containing 1% (w/v) lysozym. Proteins pGST.E1,
pGST.E2a, and pGST.E2b were expressed as inclusion bod-
ies in E. coli and harvested by centrifugation (12,000 g).
Envelope-specific proteins were partially purified by incu-
bation with lysis buffer containing 10 mM EDTA and 0.5%
Triton X-100. After vigorous shaking for 12 h at 4°C, inclu-
sion bodies were again pelleted and submitted to a second
round of incubation with lysis buffer containing 0.05% SDS.
Proteins were separated by SDS–PAGE and blotted onto
nitrocellulose (Schleicher & Schuell, FRG).
Immunization of rabbits with recombinant E1 and E2
Immunization of rabbits was performed by standard
procedures (Eurogentec, Seraing, Belgium). Briefly, par-
tially purified bacterial lysates obtained from 500 ml of
culture (approximately 3 mg of GST-specific fusion pro-
tein) were used for blotting onto nitrocellulose. HCV-
specific protein bands were cut from the blot after stain-
ing with Ponceau S. A slice of the filter (approximately
100 mg of protein) was used for immunization. Boosts
were performed at weeks 2, 4, and 8. One rabbit (R1) was
immunized with pGST.E1, and two rabbits were immu-
nized with pGST.E2a (R2 and R3) or pGST.E2b (R4 and
R5). Animals were bled 2 weeks after the last boost.
Peptide ELISA
Sixteen or 27 overlapping peptides (20-mers) were
used for ELISA to detect antibody reactivities to HCV E1
or E2, respectively. Peptides cover aa 171–340 or aa
411–690 of HCV-AD78. Peptides overlapped by 10 amino
acids and carried a biotinylated spacer at their N-termi-
nus (lysyl(e-biotinyl)-b-alanyl-e-aminohexanoyl-b-alanyl-)
(Kraas et al., 1995). ELISA plates were coated with avidin
(10 mg/ml) overnight at 4°C in carbonate buffer, pH 9.5.
Plates were washed with 1% Tween in PBS. Peptides (1
mg/ml) were solved in buffer A (20% FCS, 1% NP-40 in
PBS) and bound to microtiter wells for 2 h at 37°C. After
washing, rabbit serum (1:200) was incubated in 0.53
buffer A for 2 h at 37°C. Another washing step was
followed by incubation with peroxidase-labeled anti-rab-
bit antibody (1:4000; DAKO Diagnostika, FRG) diluted in
0.253 buffer A. After five additional washing steps, the
ELISA was developed with ABTS (Sigma, FRG) according
to standard procedures. Preimmunization sera were
used as negative controls and produced OD405 values of
0.05–0.1 (mean 0.07). Sera were scored positive when
OD405 values were above 0.25 (33 meanneg 1 15%) in at
least two experiments.
HCV binding to cells (in vitro neutralization assay)
The binding assay used was described before (Zibert
et al., 1995). Briefly, 5 ml of HCV-AD78 (2–5 3 105 PCR
HCV genome equivalents/ml) was preincubated with 20
ml of rabbit serum for 2 h at 4°C in a total volume of 100
ml. This incubation mixture was adjusted to 500 ml with
MEM medium and incubated with 2 3 106 human fibro-
blast cells (VH3) for binding of the virus. After 2 h of
incubation at room temperature, cells were washed ex-
tensively with PBS (five times). Binding of HCV to cells
was monitored by RT–PCR specific to the 59 nontrans-
lated region of HCV after RNA extraction of cells.
Statistical analysis
Statistical analysis for group comparison was per-
formed by the x2 method. Values of P , 0.005 (two tailed)
were considered a significant difference between
groups.
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